=== PAGE 4 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Suzanne Strang, Ph.D.
ASCEND Therapeutics US, LLC
NDA 021166/MA 430

                                                                                         Page 4

include a subject line that clearly identifies the submission as a Response to Untitled Letter.
OPDP reminds you that only written communications are considered official.

The violations discussed in this letter do not necessarily constitute an exhaustive list. It is
your responsibility to ensure that your promotional materials for EstroGel comply with each
applicable requirement of the FD&C Act and FDA implementing regulations.


                                                                   Sincerely,

                                                                   {See appended electronic signature page}

                                                                   Lynn Panholzer, Pharm.D.
                                                                   Regulatory Review Officer
                                                                   Division of Advertising & Promotion Review 2
                                                                   Office of Prescription Drug Promotion


                                                                   {See appended electronic signature page}

                                                                   Matthew J. Falter, Pharm.D.
                                                                   Team Leader
                                                                   Division of Advertising & Promotion Review 2
                                                                   Office of Prescription Drug Promotion













Reference ID: 4307928
